What Epitalon Reviews is, and what it is not.

What this project is

Epitalon Reviews is an independent editorial project that publishes summaries of the peer-reviewed research literature on Epitalon (Alanyl-Glutamyl-Aspartyl-Glycine, AEDG tetrapeptide). The site is not a clinic. It does not employ clinicians and does not provide medical advice. It does not manufacture, sell, or distribute any product. Its work is editorial commentary on publicly available science.

The domain modifier — 'reviews' — is editorial framing that reflects the nature of the project: every page of this site is a review of primary research, not a report of original findings. The word carries no claim about clinical services, consultations, or therapeutic recommendations. The entity behind this site is a publisher, not a practitioner.

This project began from a simple observation: the Epitalon literature is substantial (more than fifty published papers by the Khavinson group over twenty-five years, plus a small number of independent studies) but poorly indexed for readers who are not native to biogerontology. The primary papers sit behind journal paywalls or are published in journals not widely indexed in standard English-language searches. The result is that most available discussions of Epitalon online either uncritically amplify the most optimistic findings or dismiss the entire body of work without engaging its specifics. This site attempts a third register: systematic, citation-attributed, and honest about what the evidence does and does not establish.

Editorial standards

Every quantitative claim on this site is sourced to a specific publication in the references index. Dose values, lifespan percentages, fold-changes in gene expression, clinical response rates — all are drawn from the primary literature and annotated with inline citation numbers that resolve to full entries on the /references page.

The single-source caveat is treated as a first-order editorial fact, not a footnote. Nearly all Epitalon research originates from one institution (the St. Petersburg Institute of Bioregulation and Gerontology, led by Vladimir Khavinson). This concentration of the evidence base is acknowledged on every page where it applies, using a standardized callout block so that the reader always knows the epistemic context of the claims being presented.

No personal experience, anecdote, or forum report is cited as evidence. No dosing recommendation for human use appears anywhere on this site. All dose information is framed as research context — what was administered to which species in which experimental design — not as guidance.

The site does not link to vendors, pharmacies, compounding services, or any entity that manufactures or distributes Epitalon or related compounds. Phase 1 outbound links are restricted to PubMed, PubMed Central, NIH databases, ClinicalTrials.gov, peer-reviewed journal pages, and institutional educational resources.

Sourcing methodology

Primary sources were identified through PubMed and PubMed Central searches on the terms 'Epitalon,' 'Epithalon,' 'AEDG peptide,' and 'Khavinson tetrapeptide,' supplemented by backward citation searches from the 2025 Araj et al. comprehensive review ^[13]. The search was not date-limited; it captured the full published record through May 2026.

Inclusion criteria: peer-reviewed original research or review articles; English-language primary text or English abstract with sufficient methodological detail for data extraction. Conference abstracts without a full paper were not included. Inclusion was not restricted by species, endpoint, or outcome direction — studies with null findings (where the dose did not produce the reported endpoint) were included where they appear in the primary literature.

All citations were verified against their PubMed or PMC records. DOIs were confirmed where available. Where DOI was not available in the published abstract, the PubMed URL is given as the primary locator.

Disclaimer

Epitalon Reviews does not provide medical advice, diagnosis, or treatment recommendations of any kind. The content on this site is editorial commentary on publicly available peer-reviewed research and is published for educational and informational purposes. No information on this site should be interpreted as a recommendation to use, acquire, or administer any compound. Epitalon is not approved by the FDA, EMA, or any major regulatory body for human therapeutic use. Anyone considering use of any research compound should consult a licensed healthcare provider.